Articles related to OBSESSIVE-COMPULSIVE DISORDER (OCD)

Explore the latest systematic review and meta-analysis on transcranial magnetic stimulation (TMS) in OCD treatment, revealing promising results and emphasizing the need for further research to identify optimal neural targets and protocols.

In this study, participants with OCD were seen to have a complex imbalance affecting the brain pathways and regions that are linked to emotion regulation and reward. The findings point to better targets for drug therapy since current medications interventions fail to benefit many OCD sufferers.

In a study of more than 22,000 patients with schizophrenia, schizoaffective disorder, or bipolar disorder, 24% also had obsessive-compulsive symptoms; 12% had a diagnosis of OCD. Both co-morbidities were associated with higher rates of aggressive behavior, cognitive problems, and hallucinations or delusions.

NeuroStar is the first FDA-approved transcranial magnetic stimulation (TMS) system developed to treat major depressive disorders. With the new FDA approval, this TMS system will allow physicians to better treat patients with obsessive compulsive disorder (OCD) without the need for additional hardware.